Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

Selecting and sequencing therapy in previously untreated urothelial cancer

Biomarkers beyond PD-L1 expression to predict outcome to immune therapy

Date

30 Sep 2019

Session

Selecting and sequencing therapy in previously untreated urothelial cancer

Topics

Tumour Site

Urothelial Cancer

Presenters

Michiel Van der Heijden

Authors

M.S. Van der Heijden

Author affiliations

  • Urogenital Carcinogenesis, 4Netherlands Cancer Institute, 1066 - Amsterdam/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction

Presenter: Eva Comperat

Session: Selecting and sequencing therapy in previously untreated urothelial cancer

Resources:

Slides

Webcast

Conclusions and perspectives

Presenter: Joaquim Bellmunt

Session: Selecting and sequencing therapy in previously untreated urothelial cancer

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.